Novavax Covid Vaccine is on route to FDA Authorization
The shot would be the fourth authorized vaccine in the United States and the first new one since J&J’s passed authorization in 2021...
The path to authorization for Novavax’s Covid vaccine for adults has cleared a major obstacle yesterday.
A vote held yesterday by the FDA’s committee of independent vaccine experts voted 21 to 0 in an all-day meeting in which the committee weighed the pros and cons of Novavax’s data to declare it safe.
The committee’s recommendation is usually what the FDA follows and the agency can clear Novavax’s vaccine now for distribution across the nation and eventually globally.
However, even with the good news coming from the FDA, the CDC would need to sign off on the shots before any pharmacies or healthcare providers can administer the shots to everyday people.
The shot would be the fourth authorized vaccine in the United States and the first new one since J&J’s passed authorization in 2021.
The race for the development of the Covid vaccine included Novavax who received $1.8 Billion in taxpayer funding from Operation Warp Speed. Novavax sadly fell behind the competition and struggled to get manufacturing in place after clinical trial data appeared much later than the bigger names such as Pfizer and Moderna.
Read more about Novavax HERE